Author: Jerome Rosenstock
Publisher: Aspen Publishers Online
ISBN: 1454827114
Category : Chemicals
Languages : en
Pages : 6754

Get Book Here

Book Description

Author: Louis Sanford Goodman
Publisher: McGraw Hill Professional
ISBN: 0071443436
Category : Medical
Languages : en
Pages : 1232

Get Book Here

Book Description
Put the authority of Goodman & Gilman's in the palm of your hand! 5 STAR DOODY'S REVIEW! "...the most authoritative and trusted source of pharmacological information, has now spawned a portable pocket drug guide....This manual extracts the essential core drug information from the eleventh edition of the parent book, referring the reader to the online version of the parent book for historical aspects, many chemical and clinical details, and additional figures and references. This makes G & G a very useful book. This will be of use to individuals in training or practice in the fields of pharmacy, medicine, nursing, or allied health disciplines where knowledge of drug actions are important....Each chapter provides the core essential information provided in the parent book in a very readable format. Readers can use this easy to handle and read manual for essential information along with the online version of the parent book as a reference for more in-depth specific information on drugs."--Doody's Review Service The Goodman & Gilman Manual of Pharmacology and Therapeutics offers the renowned content of Goodman & Gilman's Pharmacological Basis of Therapeutics, Eleventh Edition, condensed into an ultra-handy, streamlined reference. More than just a pocket drug guide, this indispensable resource offers: A carry-along source of essential fundamental information, with all the authority of Goodman & Gilman's Pharmacological Basis of Therapeutics, Eleventh Edition The benefits of the world's leading pharmacology text in a convenient, portable format Comprehensive, yet streamlined and clinically relevant coverage of the pharmacological basis of therapeutics High-yield overview of pharmacokinetics, pharmacodynamics, and the foundations of pharmacology Expert insights into the properties, mechanisms, and uses of all the major drug classes Considerations of vital patient-specific issues

Author: Kung-Chung Liu
Publisher: Springer Nature
ISBN: 981138102X
Category : Law
Languages : en
Pages : 513

Get Book Here

Book Description
This open access book analyses intellectual property codification and innovation governance in the development of six key industries in India and China. These industries are reflective of the innovation and economic development of the two economies, or of vital importance to them: the IT Industry; the film industry; the pharmaceutical industry; plant varieties and food security; the automobile industry; and peer production and the sharing economy. The analysis extends beyond the domain of IP law, and includes economics and policy analysis. The overarching concern that cuts through all chapters is an inquiry into why certain industries have developed in one country and not in the other, including: the role that state innovation policy and/or IP policy played in such development; the nature of the state innovation policy/IP policy; and whether such policy has been causal, facilitating, crippling, co-relational, or simply irrelevant. The book asks what India and China can learn from each other, and whether there is any possibility of synergy. The book provides a real-life understanding of how IP laws interact with innovation and economic development in the six selected economic sectors in China and India. The reader can also draw lessons from the success or failure of these sectors.

Author: Hyewon Ahn
Publisher: Nomos Verlagsgesellschaft Mbh & Company
ISBN: 9783832965242
Category : Law
Languages : en
Pages : 75

Get Book Here

Book Description
This LL.M thesis is a response to the recent decisions of the German Federal Court of Justice on the patentability requirements of selection inventions, namely the Olanzapine and Escitalopram decisions. The thesis provides an overview on the technology and patenting practice, followed by the discussion of jurisprudence on the patentability requirements for selection inventions in major jurisdictions. In particular, the paper examines the novelty and the non-obviousness requirements. As the discussion on the anticipation and obviousness is more contentious in selection inventions, it discusses the issues in view of the two decisions. Post-grant impact of selection inventions and their meanings to the system of patent are explored and some comparative perspectives on selection inventions are discussed. In conclusion, by exploring the significance of granting patents on selection invention to the working of patent system, the paper provides a useful analysis in understanding patentability requirements thereof, beyond the pharmaceutical industry sector. LL.M Thesis. (Series: Munich Intellectual Property Law Center - MIPLC - Vol. 12)

Author: David Cavalla
Publisher: Royal Society of Chemistry
ISBN: 1839163402
Category : Medical
Languages : en
Pages : 350

Get Book Here

Book Description
Drug repurposing is the development of existing drugs for new uses: given that 9 in 10 drugs that enter drug development are never marketed and therefore represent wasted effort, it is an attractive as well as inherently more efficient process. Three repurposed drugs can be brought to market for the same cost as one new chemical entity; and they can also be identified more quickly, an important benefit for patients whose diseases are progressing faster than therapeutic innovation. But repurposing also requires a fresh look at configuring pharmaceutical R&D, considering clinical, regulatory and patent issues much earlier than would otherwise be the case; a holistic gedanken experiment almost needs to be undertaken at the very start of any repurposing development. In addition to new ways of thinking, the discovery of repurposing opportunities can take advantage of artificial intelligence techniques to match the perfect new use for an existing drug. And while repurposing of medicines has been in the mind of every doctor since Hypocrates, modern clinical practice will simply have to adapt to new repurposing techniques in an age where the number of known diseases is increasing much faster than the healthcare dollars available.

Author: Philip W. Grubb
Publisher: Oxford University Press, USA
ISBN:
Category : Business & Economics
Languages : en
Pages : 552

Get Book Here

Book Description
Previous editions, 1st and 2nd, published under titles : 1st (1982) Patents for chemists ; 2nd (1986) Patents in chemistry and biotechnology ; 3rd edition published in 1999.

Author: Institute of Medicine
Publisher: National Academies Press
ISBN: 030904491X
Category : Medical
Languages : en
Pages : 225

Get Book Here

Book Description
Americans praise medical technology for saving lives and improving health. Yet, new technology is often cited as a key factor in skyrocketing medical costs. This volume, second in the Medical Innovation at the Crossroads series, examines how economic incentives for innovation are changing and what that means for the future of health care. Up-to-date with a wide variety of examples and case studies, this book explores how payment, patent, and regulatory policiesâ€"as well as the involvement of numerous government agenciesâ€"affect the introduction and use of new pharmaceuticals, medical devices, and surgical procedures. The volume also includes detailed comparisons of policies and patterns of technological innovation in Western Europe and Japan. This fact-filled and practical book will be of interest to economists, policymakers, health administrators, health care practitioners, and the concerned public.

Author: Ellen F. M. 't Hoen
Publisher:
ISBN: 9789079700066
Category : Agreement on Trade-Related Aspects of Intellectual Property Rights
Languages : en
Pages : 136

Get Book Here

Book Description
In The Global Politics of Pharmaceutical Monopoly Power, researcher and global advocate Ellen 't Hoen explains how new global rules for pharmaceutical patenting impact access to medicines in the developing world. The book gives an account of the current debates on intellectual property, access to medicines, and medical innovation, and provides historical context that explains how the current system emerged. This book supports major policy changes in the management of pharmaceutical patents and the way medical innovation is financed in order to protect public health and, in particular, promote access to essential medicines for all. The Open Society Institute provided support to translate this report into Russian.

Author: Robin Feldman
Publisher: Cambridge University Press
ISBN: 131673949X
Category : Law
Languages : en
Pages : 165

Get Book Here

Book Description
While the shockingly high prices of prescription drugs continue to dominate the news, the strategies used by pharmaceutical companies to prevent generic competition are poorly understood, even by the lawmakers responsible for regulating them. In this groundbreaking work, Robin Feldman and Evan Frondorf illuminate the inner workings of the pharmaceutical market and show how drug companies twist health policy to achieve goals contrary to the public interest. In highly engaging prose, they offer specific examples of how generic competition has been stifled for years, with costs climbing into the billions and everyday consumers paying the price. Drug Wars is a guide to the current landscape, a roadmap for reform, and a warning of what is to come. It should be read by policymakers, academics, patients, and anyone else concerned with the soaring costs of prescription drugs.

Author: Oliver Gassmann
Publisher: Springer Science & Business Media
ISBN: 3540247815
Category : Business & Economics
Languages : en
Pages : 184

Get Book Here

Book Description
Pharmaceutical giants have been doubling their investments in drug development, only to see new drug approvals to remain constant for the past decade. This book investigates and highlights a set of proactive strategies. The authors focus on three sources of pharmaceutical innovation: new management methods, new technologies, and new forms of internationalization. Their findings are illustrated in the case of the Swiss pharmaceutical industry, the leading exporter of pharmaceutical products in percentage of GDP, and some of its main pharmaceutical firms such as Novartis and Hoffmann-La Roche.